Vyne Therapeutics Inc Stock Price, News & Analysis

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced on February 28, 2023, that it has regained compliance with Nasdaq's minimum bid price requirement. The company received a Notification Letter indicating that its common stock's closing bid price was at $1.00 per share or greater for the last 10 consecutive business days, from February 13 to February 27, 2023. VYNE is focused on developing innovative therapies for immuno-inflammatory conditions, utilizing its proprietary bromodomain & extra-terminal (BET) domain platform, which includes lead programs VYN201 and VYN202.

VYNE Therapeutics Inc. (Nasdaq: VYNE), a clinical-stage biopharmaceutical company, announced that CEO David Domzalski will participate in a fireside chat at the 43rd Annual Cowen Health Care Conference on March 7, 2023. The event will take place at 2:10 PM ET at the Boston Marriott Copley Place, where management will also hold 1-on-1 meetings with investors. A webcast link is provided for attendees to view the session online. The webcast replay will be accessible for 90 days post-conference. VYNE is focused on developing therapies for immuno-inflammatory conditions through its proprietary bromodomain & extra-terminal (BET) domain platform.

VYNE Therapeutics announced positive results from the Phase 1a trial of VYN201, a novel BET inhibitor for treating vitiligo. The study involved 30 healthy volunteers who received topically applied doses without any serious adverse events, confirming safety and tolerability. Key findings include no clinically relevant treatment emergent adverse events and no withdrawals from the trial. VYNE plans to evaluate selected doses in the ongoing Phase 1b trial involving non-segmental vitiligo patients, with results expected in mid-2023. The company aims to advance its BET inhibitor program as a differentiated therapy with promising efficacy and safety.

VYNE Therapeutics Inc. announced a 1-for-18 reverse stock split effective after market close on February 10, 2023. This move aims to help the company comply with the $1.00 minimum bid price standard for continued listing on the Nasdaq Capital Market. Following the split, approximately 3,251,871 shares will be outstanding, down from 58,533,691. The decision was endorsed by shareholders on January 12, 2023. All stockholders will see their shares adjusted automatically, and those with fractional shares will receive cash compensation. VYNE continues to focus on developing therapies for immuno-inflammatory conditions.

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced the dosing of the first vitiligo patient in its Phase 1a/b clinical trial for VYN201, a pan-BET inhibitor aimed at treating immuno-inflammatory conditions. This milestone follows IND clearance and enrollment of healthy volunteers. The trial is designed to assess safety and pharmacokinetic data (Phase 1a) and early clinical proof-of-concept in vitiligo patients (Phase 1b), with topline data expected in the first half of 2023. Vitiligo affects 0.5-2% of the global population, with limited treatment options currently available.

VYNE Therapeutics Inc. (Nasdaq: VYNE) is set to participate in the LifeSci Partners 12th Annual Corporate Access Event during the J.P. Morgan Healthcare Conference in San Francisco, CA. Scheduled for January 10-11, 2023, the company will conduct one-on-one meetings at the Beacon Grand Hotel.

VYNE focuses on developing innovative therapies for immuno-inflammatory conditions, utilizing its proprietary bromodomain & extra-terminal (BET) domain platform, which includes lead programs VYN201 and VYN202.

VYNE Therapeutics has announced the granting of a new patent (GB Patent No. 2597228) for its VYN201 program by the UK’s Intellectual Property Office, expiring in April 2040. This patent, derived from a PCT application filed by The University of Dundee, supports VYNE's ongoing development of its pan-BET inhibitor, VYN201, currently in a Phase 1a/b clinical trial for vitiligo. The company anticipates further patent approvals and believes VYN201 could offer broad therapeutic utility across various inflammatory conditions.

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced that its President and CEO, David Domzalski, will present at Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference on December 8, 2022. The presentation titled Hit or Miss: Companies with 2023 Readouts & Launches to Keep in Focus will take place from 10:00 to 10:45 a.m. ET. VYNE focuses on innovative therapies for immuno-inflammatory conditions, leveraging its unique bromodomain & extra-terminal (BET) domain platform, including lead programs VYN201 and VYN202.

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced participation in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022. CEO David Domzalski will present at 12:30 p.m. ET and management will host investor meetings on the same day. A webcast link is provided for those interested in attending, with a replay available for 90 days post-event. VYNE is focused on developing innovative therapies for immuno-inflammatory conditions, utilizing its proprietary BET domain platform, including lead programs VYN201 and VYN202.